Skip to main content

Geron Corp

GERN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000886744

No open-market purchases or sales by Geron Corp insiders were filed in the last 90 days; 260 institutions reported holding it in 13F filings for Q2 2026, worth $626.1M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +6 vs. previous quarter
260
13F valueReported value at the end of Q2 2026
$626.1M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding GERN, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding GERN at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Geron Corp insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 19, 2026 (view filing)Feb 181 dayRobertson MichelleEVP, CHIEF FINANCIAL OFFICERSSale−9.86K$1.94−$19.1K−35.8%17.6K after
May 13, 2025 (view filing)May 94 daysLawlis V BryanDirectorPPurchase+13.3K$1.18+$15.7KNew position13.3K after
Mar 3, 2025 (view filing)Feb 274 daysSamuels Scott AlanEVP, Chief Legal OfficerPPurchase+15.0K$1.61+$24.1K+128.4%26.7K after
Mar 3, 2025 (view filing)Feb 274 daysScarlett John AChairman, President and CEOPPurchase+12.5K$1.77+$22.1KNew position12.5K after
Mar 3, 2025 (view filing)Feb 274 daysZiegler JamesEVP, Chief Commercial OfficerPPurchase+100.0K$1.60+$160.0KNew position100.0K after
Jul 10, 2024 (view filing)Jul 82 daysGrethlein Andrew JEVP, Chief Operating OfficerSSale−674.3K$4.56−$3.08M−100.0%0 after
Jun 12, 2024 (view filing)Jun 102 daysFeller FayeEVP, Chief Medical OfficerSSale−287.9K$4.63−$1.33M−100.0%0 after
Jun 12, 2024 (view filing)Jun 102 daysKapur AnilEVP, Corp Strategy & CCOSSale−421.9K$4.65−$1.96M−100.0%0 after
Jun 5, 2024 (view filing)Jun 41 dayScarlett John AChairman, President and CEOSSale−600.0K$4.00−$2.40M−50.0%600.0K after
May 17, 2024 (view filing)May 152 daysLawlis V BryanDirectorSSale−35.0K$3.75−$131.3K−100.0%0 after10b5-1

Top 10 13F holders, Q2 2026

The largest institutional positions in Geron Corp at the end of Q2 2026; share changes are against Q1 2026.

See all 260 holders
Institutions holding GERN in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.49,115,571$62.9M0.00%+1,795,792+3.8%Added
Ra Capital Management, L.P.42,809,751$54.8M0.48%−20,961,615−32.9%Reduced
Soleus Capital Management, L.P.42,808,659$54.8M1.89%+1,300,000+3.1%Added
State Street Corp35,856,671$45.9M0.00%+5,359,488+17.6%Added
Citadel Advisors LLC29,038,928$37.2M0.02%+7,462,359+34.6%Added
Vanguard Capital Management LLC27,250,215$34.9M0.00%+581,186+2.2%Added
Nantahala Capital Management, LLC24,450,000$31.3M0.95%+13,225,000+117.8%Added
Clearbridge Investments, LLC19,648,853$25.2M0.02%+28,533+0.1%Added
Eversept Partners, LP18,717,422$24.0M1.31%−117,461−0.6%Reduced
Goldman Sachs Group Inc16,633,368$21.3M0.00%+5,456,777+48.8%Added